SCHEMBL24107482

SCHEMBL24107482

COC(=O)c1ccc(C2=CCSCC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 4/20 0.44
▸ CA2 P00918 4/20 0.44
▸ CA12 O43570 3/20 0.44
▸ CA9 Q16790 3/20 0.44
▸ CA14 Q9ULX7 3/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ TSHR P16473 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ MAPT P10636 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ SETD7 Q8WTS6 1/20 0.41
▸ LOXL2 Q9Y4K0 1/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ PTGS1 P23219 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24107668 0.80 MAPK1 (0.47) MAPTKDM4E
SCHEMBL9295486 0.80 CA1 (0.53) CA1CA2CA12CA9CA14
SCHEMBL26090324 0.76 CA1 (0.48) CA1CA2CA12CA9CA14
SCHEMBL2944680 0.74 ALDH1A1 (0.48) CA1CA2CA12CA9CA14
SCHEMBL2950950 0.73 ALDH1A1 (0.47) CA1CA2CA12CA9CA14
SCHEMBL2949298 0.73 ALDH1A1 (0.47) CA1CA2CA12CA9CA14
SCHEMBL2949295 0.73 ALDH1A1 (0.47) CA1CA2CA12CA9CA14
SCHEMBL613237 0.73 CA1 (0.46) CA1CA2CA12CA9CA14
SCHEMBL19387238 0.73 CA1 (0.70) CA1CA2CA12CA9CA14
Biphenyl Dimethyl Dicarboxylate SCHEMBL68521 0.73 CA1 (0.70) CA1CA2CA12CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212131-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-07-06 — — US disclosed
US-20230212131-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-07-06 — — US disclosed
US-20230212131-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-07-06 — — US disclosed
EP-4161921-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF Anima Biotech Inc. (US) 2023-04-12 — — EP disclosed
CN-115916776-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2023-04-04 — — CN disclosed
WO-2021252555-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-12-16 — — WO disclosed
WO-2021252555-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212131-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 CA1 4669/4885CA2 4469/4885CA12 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback